 | |
| Company type | Public |
|---|---|
| Industry | Biotechnology |
| Founded | 1 January 2004  |
| Headquarters | Pasadena, California, U.S. |
Key people | Christopher Anzalone, Ph.D., (president and CEO) |
| Revenue |  US$$829.4 million (2025)[1] |
Number of employees | 609 |
| Website | arrowheadpharma |
Arrowhead Pharmaceuticals, Inc. is a publicly traded biopharmaceutical company based in Pasadena, California. Arrowhead's products in development act throughRNA interference (RNAi) mechanisms of action.[2][3] The company focuses on treatments forhepatitis B, liver disease associated withalpha 1-antitrypsin deficiency andcardiovascular disease.[2]
In 2015, the company substantially expanded its intellectual property holdings through complete acquisition of the fullRNAi research and development portfolio, and assets fromNovartis.[4][5]
In April 2016, the company announced a name change from Arrowhead Research Corporation to Arrowhead Pharmaceuticals, Inc.[6]
In September 2016, Arrowhead entered into two collaboration and licensing agreements withAmgen. Under the deals,Amgen received a worldwide exclusive license to Arrowhead's ARO-LPARNAi program and an option to a worldwide exclusive license for ARO-AMG1, both for cardiovascular disease.[7]
On Oct. 31, 2018, Arrowhead Pharmaceuticals Inc. closed on a $3.7 billion license and collaboration agreement with Janssen to develop and commercialize ARO-HBV. As part of the deal, Arrowhead entered into a research collaboration and option agreement with Janssen to potentially collaborate for up to three more RNA interference (RNAi) therapeutics against new targets to be selected by Janssen.[8]
The company has sixteen products in its pipeline, in various stages of development.[2]
| Product | Indication | Development phase | Notes |
|---|---|---|---|
| ARO-HBV[2] | Hepatitis B | In clinic, phase 2 | Licensed withJanssen, Phase 2 |
| ARO-AAT[2] | Alpha-1 antirypsin deficiency | In clinic, phase 3 | Orphan Drug designation, partnered withTakeda |
| ARO-APOC3[2] | Hypertriglyceridemia | Phase 2, 3 | Orphan Drug designation,Fast Track Designation, Phase 3 for FCS, Phase 2 for expanded populations |
| ARO-HIF2[2] | Renal cell carcinoma | Preclinical | Second generation being worked on presumably |
| ARO-ENaC[2] | Cystic fibrosis | Preclinical | Second generation being worked on in preclinic |
| ARO-ANG3[2] | Dyslipidemia | In clinic, Phase 2 | Orphan Drug designation |
| Olpasiran/ AMG 890[2] | Cardiovascular disease | In clinic, phase 3 | Partnered withAmgen |
| ARO-PNPLA3 | NASH | In clinic, Phase 1 | License returned to ARWR |
| ARO-HSD | NASH | In clinic, Phase 1 | Licensed toGSK |
| ARO-C3 | Complement Mediated Disease | In clinic, Phase 1 | |
| ARO-MUC5AC | Muco-obstructive | In clinic, Phase 1 | |
| ARO-RAGE | Inflammatory | In clinic, Phase 1 | |
| ARO-MMP7 | Idiopathic Pulmonary Fibrosis | In clinic, Phase 1 | |
| ARO-COV | COVID-19 | Preclinical | |
| ARO-DUX4 | FSHD | Preclinical | |
| HZN-457 | Gout | In clinic, Phase 1 | Partnered withHorizon |